Compare CPAY & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAY | ILMN |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 20.4B |
| IPO Year | 2010 | 2000 |
| Metric | CPAY | ILMN |
|---|---|---|
| Price | $317.75 | $119.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 17 |
| Target Price | ★ $378.91 | $124.24 |
| AVG Volume (30 Days) | 687.6K | ★ 1.9M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.59 | ★ 170.87 |
| EPS | ★ 15.03 | 5.45 |
| Revenue | ★ $4,528,403,000.00 | $4,343,000,000.00 |
| Revenue This Year | $18.85 | $6.52 |
| Revenue Next Year | $10.52 | $5.49 |
| P/E Ratio | $21.36 | ★ $21.19 |
| Revenue Growth | ★ 13.93 | N/A |
| 52 Week Low | $252.84 | $68.70 |
| 52 Week High | $361.99 | $155.53 |
| Indicator | CPAY | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 40.20 |
| Support Level | $314.57 | $114.88 |
| Resistance Level | $338.47 | $135.68 |
| Average True Range (ATR) | 11.07 | 4.53 |
| MACD | -1.97 | -0.34 |
| Stochastic Oscillator | 23.08 | 19.13 |
Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. The company offers payment and spend management solutions, including accounts payable automation, cross-border payments, commercial card programs, vehicle payment solutions, and lodging payment services. Its reportable segments are: Corporate Payments, Vehicle Payments, Lodging Payments and Other. The majority of the company's revenue is derived from the Vehicle Payments segment, which helps customers to pay for vehicle related expenses. Geographically, it derives the maximum revenue from the United States and the rest from Brazil, the United Kingdom and other countries.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.